Mindset Pharma has created an innovative, patent-pending intranasal platform formulation technology.
Improved central nervous system (CNS) penetration of first and later generations of psychedelic drugs is anticipated as a result of the new technology.
The pharmacokinetic profile of the active pharmaceutical ingredient is changed by Mindset's revolutionary intranasal formulation technology, which makes use of its distinctive platform technology, a component shared by several of Mindset's top psychedelic drug candidates.
In comparison to other 5-methoxy-N,N-dimethyltryptamine formulations (5-MeO-DMT), the proof of concept (PoC) of this new formulation shows enhanced CNS penetration.
Additionally, data show a roughly 3-fold increase in CSF exposure compared to plasma when compared to a typical formulation.
With the use of this innovative formulation technique, it may be possible to lower the dose, accelerate brain absorption and outtake, and lessen peripheral side effects, making the treatment more effective, safe, and affordable.
